Regenicin, Inc. just announced that Dr. Craig Eagle, who sits on the Regenicin Board of Directors, attended The World Stem Cells and Regenerative Medicine Congress 2011 in an effort to further Regencin’s push towards obtaining FDA approval for the commercial sale of its first product candidate.
The World Stem Cells and Regenerative Medicine Congress is recognized for offering a senior director-level, interactive conference experience. Speakers and panelists include industry leaders from throughout Europe, North America and Asia. The World Stem Cells and Regenerative Medicine Congress is Europe’s most progressive strategic conference where ideas, intelligence and relationships really make a difference.
“The World Stem Cells and Regenerative Medicine Congress plays a vital role in advancing awareness of the most ground-breaking developments in the field, recognizing key industry leaders, and facilitating top level conversations about strategic planning and partnerships,” stated Randall McCoy, CEO of Regenicin. “It is great to see that Regenicin is perfectly in line with stem cell technology that is being pursued by the rest of the world.”
Regenicin, Inc. is a biotechnology company with corporate headquarters in Little Falls, New Jersey. The Company specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs. With a solid business model in place, Regenicin is positioning itself to become a leader in one of the fastest growing industries in biotechnology.
Let us hear your thoughts: Regenicin, Inc. Message Board